A global specialty pharmaceutical company focused on chronic endocrine diseases
Dedicated to bringing products to the global endocrine market
Focused on addressing the major unmet clinical and patient needs for patients with chronic endocrine diseases
Innovative research activities focused on circadian-based endocrinology
Diurnal is a UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.
The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.
To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.
The presentation will be presented by Deborah P. Merke, MD, MS, from NIH Clinical Center and NICHD, Bethesda, MD, USA, at ENDO Online 2020.
Arrangements in place to ensure constant drug supply to patients across Europe
European regulatory recommendation for approval targeted for Q1 2021
You are leaving http://www.diurnal.co.uk .Links to all outside websites are provided as a resource to our visitors. Outside websites are neither owned or controlled by Diurnal Ltd. Diurnal accepts no responsibility for the content of other websites.×